REBEL Core Cast 8.0 – The NEJM + Non-Inferiority Studies

Take Home Points on Non-Inferiority Studies

  • Non-inferiority studies should be done when a new treatment (or diagnostic modality) requires less resources (cost or time), is easier for the patient or has a lower side-effect profile.
  • Non-inferiority study design largely negates the protections against bias added by blinding and randomization.
  • Non-inferiority studies can be used to manipulate clinicians when a superiority study would be more appropriate.

REBEL Core Cast 8.0 – The NEJM + Non-Inferiority Studies

Click here for Direct Download of Podcast



  1. Stets R et al. Omadacycline for Community-Acquired Bacterial Pneumonia. NEJM 2019; 380(6): 511-27. PMID: 30726692
  2. O’Riordan W et al. Omadacycline for Acute Bacterial Skin and Skin-Structure Infections. NEJM 2019; 380(6): 528-38. PMID: 30726689
  3. Lundh A et al. Industry sponsorship and research outcome: systematic review with meta-analysis. Intensive Care Med 2018; 44(10): 1603-12. PMID: 30132025

Show Notes Written By: Miguel Reyes, MD (Twitter: @Miguel_ReyesMD)

Post Peer Reviewed By: Salim R. Rezaie, MD (Twitter: @srrezaie)

Cite this article as: Anand Swaminathan, "REBEL Core Cast 8.0 – The NEJM + Non-Inferiority Studies", REBEL EM blog, April 3, 2019. Available at:
The following two tabs change content below.

Anand Swaminathan

Clinical Assistant Professor of Emergency Medicine at St. Joe's Regional Medical Center (Paterson, NJ)
REBEL EM Associate Editor and Author

Like this article?

Share on facebook
Share on Facebook
Share on twitter
Share on Twitter
Share on linkedin
Share on Linkdin
Share on email
Share via Email

Want to support rebelem?

3 thoughts on “REBEL Core Cast 8.0 – The NEJM + Non-Inferiority Studies”

  1. Swami, I salute you for standing up for intellectual integrity! Terrific episode. The profound disappointment I feel towards the corruption of the iconic NEJM cannot be overstated. Thanks for presenting a balanced criticism and viewpoint.


Leave a Comment

Time limit is exhausted. Please reload CAPTCHA.